Abstract
Fludarabine is a comparatively new drug for the treatment of low-grade lymphoid malignancy. This report describes five cases of unusual neurological illnesses occurring after treatment with fludarabine. These suggest that caution should be exercised in patients receiving fludarabine who develop neurological abnormalities, with prompt investigation and if necessary cessation of the drug.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chun H. G., Leyland-Jones B. R., Caryk S. M., Hoth D. F. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep. 1986 Oct;70(10):1225–1228. [PubMed] [Google Scholar]
- Cohen R. B., Abdallah J. M., Gray J. R., Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med. 1993 Jan 15;118(2):114–116. doi: 10.7326/0003-4819-118-2-199301150-00007. [DOI] [PubMed] [Google Scholar]
- Hochster H. S., Kim K. M., Green M. D., Mann R. B., Neiman R. S., Oken M. M., Cassileth P. A., Stott P., Ritch P., O'Connell M. J. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol. 1992 Jan;10(1):28–32. doi: 10.1200/JCO.1992.10.1.28. [DOI] [PubMed] [Google Scholar]
- Keating M. J., Kantarjian H., O'Brien S., Koller C., Talpaz M., Schachner J., Childs C. C., Freireich E. J., McCredie K. B. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol. 1991 Jan;9(1):44–49. doi: 10.1200/JCO.1991.9.1.44. [DOI] [PubMed] [Google Scholar]
- Keating M. J., O'Brien S., Kantarjian H., Plunkett W., Estey E., Koller C., Beran M., Freireich E. J. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993 Jun 1;81(11):2878–2884. [PubMed] [Google Scholar]
- Kornblau S. M., Cortes-Franco J., Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia. 1993 Mar;7(3):378–383. [PubMed] [Google Scholar]
- Merkel D. E., Griffin N. L., Kagan-Hallet K., Von Hoff D. D. Central nervous system toxicity with fludarabine. Cancer Treat Rep. 1986 Dec;70(12):1449–1450. [PubMed] [Google Scholar]
- Puccio C. A., Mittelman A., Lichtman S. M., Silver R. T., Budman D. R., Ahmed T., Feldman E. J., Coleman M., Arnold P. M., Arlin Z. A. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol. 1991 Sep;9(9):1562–1569. doi: 10.1200/JCO.1991.9.9.1562. [DOI] [PubMed] [Google Scholar]
- Spriggs D. R., Stopa E., Mayer R. J., Schoene W., Kufe D. W. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986 Nov;46(11):5953–5958. [PubMed] [Google Scholar]
- Suzuki J., Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969 Mar;20(3):288–299. doi: 10.1001/archneur.1969.00480090076012. [DOI] [PubMed] [Google Scholar]
- Von Hoff D. D. Phase I clinical trials with fludarabine phosphate. Semin Oncol. 1990 Oct;17(5 Suppl 8):33–38. [PubMed] [Google Scholar]
- Warrell R. P., Jr, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986 Jan;4(1):74–79. doi: 10.1200/JCO.1986.4.1.74. [DOI] [PubMed] [Google Scholar]
- Whelan J. S., Davis C. L., Rule S., Ranson M., Smith O. P., Mehta A. B., Catovsky D., Rohatiner A. Z., Lister T. A. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer. 1991 Jul;64(1):120–123. doi: 10.1038/bjc.1991.253. [DOI] [PMC free article] [PubMed] [Google Scholar]